Opportunity Information: Apply for RFA DK 23 004
The Human Islet Research Network - Consortium on Modeling Autoimmune Diabetes (HIRN-CMAD) funding opportunity (RFA-DK-23-004) is a National Institutes of Health (NIH) cooperative agreement designed to push forward better experimental models of type 1 diabetes (T1D). The core purpose is to build and refine both in vitro and in vivo systems that more faithfully capture human autoimmune diabetes biology. These models are meant to help researchers study human T1D pathophysiology in a controlled way and to provide practical platforms for preclinical testing of potential new interventions, with the emphasis on tools that can predict and explain human disease mechanisms rather than relying solely on traditional animal models that may not translate well.
CMAD sits within the broader Human Islet Research Network (HIRN), meaning awardees are expected to operate as part of a coordinated consortium rather than as isolated, single-lab projects. As a cooperative agreement, NIH staff typically play an active partnership role compared with standard investigator-initiated grants, often involving substantial programmatic involvement, shared priorities, and collaborative milestones. The NOFO uses the UG3/UH3 phased award structure and is labeled "Clinical Trial Not Allowed," signaling that the work should focus on model development, validation, and preclinical-style assessments rather than testing interventions in human participants as clinical trials.
Eligible applicants are broad and include many types of U.S.-based organizations and governmental entities. Examples listed include state, county, city or township, and special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; tribal organizations that are not federally recognized; public housing authorities/Indian housing authorities; nonprofits (both 501(c)(3) and non-501(c)(3)); for-profit organizations (other than small businesses); and small businesses. The NOFO also explicitly calls out additional eligible groups such as Alaska Native and Native Hawaiian Serving Institutions, AANAPISI institutions, Hispanic-serving institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, eligible federal agencies, regional organizations, tribal governments that are not federally recognized, and U.S. territories or possessions.
Foreign eligibility is limited in a way that is common for NIH opportunities tied to U.S.-based consortia. Non-domestic (non-U.S.) entities and non-U.S. institutions are not eligible to apply as the applicant organization, and non-domestic components of U.S. organizations are also not eligible to apply. However, "foreign components" as defined by the NIH Grants Policy Statement are allowed, which generally means a U.S. applicant can include certain well-justified international elements of the project (for example, specialized assays, unique expertise, or access to resources) as a component of the work, subject to NIH rules and approval.
Administratively, the opportunity is categorized as discretionary funding and uses a cooperative agreement funding instrument. The activity area is health (and also listed under food and nutrition/health categories), with CFDA numbers 93.847 and 93.855. The original application due date listed is March 20, 2024. The award ceiling shown is $750,000. The overall emphasis is on enabling next-generation modeling approaches that can illuminate how autoimmune attack and beta cell dysfunction unfold in humans and that can serve as dependable testbeds for evaluating new T1D therapeutic concepts before they move toward human trials.Apply for RFA DK 23 004
- The National Institutes of Health in the food and nutrition, health sector is offering a public funding opportunity titled "Human Islet Research Network - Consortium on Modeling Autoimmune Diabetes (HIRN-CMAD) (UG3/UH3 Clinical Trial Not Allowed)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.847, 93.855.
- This funding opportunity was created on 2023-10-11.
- Applicants must submit their applications by 2024-03-20. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $750,000.00 in funding.
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs): HIRN-CMAD (RFA-DK-23-004)
What is the HIRN-CMAD funding opportunity (RFA-DK-23-004)?
The Human Islet Research Network - Consortium on Modeling Autoimmune Diabetes (HIRN-CMAD) funding opportunity (RFA-DK-23-004) is an NIH cooperative agreement focused on advancing better experimental models of type 1 diabetes (T1D). The goal is to develop and refine model systems that more accurately reflect human autoimmune diabetes biology.
What is the main purpose of this opportunity?
The core purpose is to build and improve both in vitro and in vivo models that more faithfully capture human T1D pathophysiology. These models are intended to help researchers study disease mechanisms in controlled settings and provide practical platforms for preclinical testing of potential interventions, with an emphasis on approaches that better predict and explain human disease biology than traditional animal models that may not translate well.
What kinds of models does the program emphasize?
The opportunity emphasizes next-generation modeling approaches, specifically including both in vitro and in vivo systems, with a priority on faithfully capturing human autoimmune diabetes biology and enabling controlled study of human T1D mechanisms.
How does this opportunity address limitations of traditional animal models?
The emphasis is on tools and model systems that can predict and explain human disease mechanisms rather than relying solely on traditional animal models, which may not translate well to human T1D. The program aims to improve the relevance of experimental models to human biology.
Is this opportunity focused on clinical trials in human participants?
No. The opportunity is labeled "Clinical Trial Not Allowed." The described focus is on model development, refinement, validation, and preclinical-style assessments rather than testing interventions in humans as clinical trials.
What does the UG3/UH3 phased award structure mean for this program?
The NOFO uses a UG3/UH3 phased award structure. Based on the description provided, this indicates a phased approach intended to support model development and related work in structured stages rather than a single continuous project format.
What does it mean that this is an NIH cooperative agreement?
This opportunity uses a cooperative agreement funding instrument, meaning NIH staff typically have an active partnership role compared with standard investigator-initiated grants. This often involves substantial programmatic involvement, shared priorities, collaboration expectations, and coordinated milestones.
How does HIRN-CMAD relate to HIRN?
CMAD sits within the broader Human Islet Research Network (HIRN). Awardees are expected to operate as part of a coordinated consortium rather than as isolated, single-lab projects.
Does the program require consortium-style participation?
Yes. The description states that awardees are expected to function within a coordinated consortium structure as part of HIRN, rather than operating as independent, standalone projects.
What is the funding type and how is it categorized administratively?
Administratively, the opportunity is categorized as discretionary funding and uses a cooperative agreement funding instrument.
What is the activity area for this opportunity?
The activity area is health, and it is also listed under food and nutrition/health categories.
What CFDA numbers are associated with this opportunity?
The CFDA numbers listed for this opportunity are 93.847 and 93.855.
What is the application due date?
The original application due date listed is March 20, 2024.
What is the award ceiling for this opportunity?
The award ceiling shown is $750,000.
Who is eligible to apply?
Eligible applicants are broad and include many types of U.S.-based organizations and governmental entities. Examples listed include state, county, city or township, and special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; tribal organizations that are not federally recognized; public housing authorities/Indian housing authorities; nonprofits (both 501(c)(3) and non-501(c)(3)); for-profit organizations (other than small businesses); and small businesses.
Are U.S. territories or possessions eligible?
Yes. The eligibility list explicitly includes U.S. territories or possessions.
Are faith-based or community-based organizations eligible?
Yes. Faith-based or community-based organizations are explicitly called out as eligible.
Are minority-serving institutions explicitly included as eligible applicants?
Yes. The NOFO explicitly calls out eligibility for Alaska Native and Native Hawaiian Serving Institutions, AANAPISI institutions, Hispanic-serving institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), and other specified groups.
Can for-profit organizations apply?
Yes. For-profit organizations (other than small businesses) are listed as eligible applicants, and small businesses are also listed as eligible.
Can federal agencies apply?
Yes. The eligibility list includes eligible federal agencies.
Are non-U.S. (foreign) organizations eligible to apply as the applicant?
No. Non-domestic (non-U.S.) entities and non-U.S. institutions are not eligible to apply as the applicant organization under this opportunity.
Can a non-domestic component of a U.S. organization apply?
No. Non-domestic components of U.S. organizations are also not eligible to apply.
Are foreign components allowed at all?
Yes. "Foreign components" as defined by the NIH Grants Policy Statement are allowed. This generally means a U.S. applicant may include certain well-justified international elements of the project, subject to NIH rules and approval.
What is an example of an allowable foreign component?
The description provides examples such as specialized assays, unique expertise, or access to resources that may be located internationally, included as a component of the work when justified and consistent with NIH policy.
What is the overarching scientific emphasis of the funded work?
The emphasis is on enabling modeling approaches that illuminate how autoimmune attack and beta cell dysfunction unfold in humans, and on creating dependable testbeds for evaluating new T1D therapeutic concepts before they progress toward human trials.
What kinds of research outcomes is HIRN-CMAD trying to enable?
The intended outcomes include more faithful experimental models of human autoimmune diabetes, improved ability to study T1D pathophysiology in controlled settings, and stronger preclinical platforms that can support evaluation of potential interventions with better relevance to human disease mechanisms.
Browse more opportunities from the same category: Food and Nutrition, Health
Next opportunity: Long-Term Ecological Research
Previous opportunity: OVW Fiscal Year 2023 National Deaf Services Program Invitation to Apply
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA DK 23 004
Applicants also applied for:
Applicants who have applied for this opportunity (RFA DK 23 004) also looked into and applied for these:
| Funding Opportunity |
|---|
| Silvio O. Conte Digestive Diseases Research Core Centers (P30 Clinical Trial Optional) Apply for RFA DK 25 003 Funding Number: RFA DK 25 003 Agency: National Institutes of Health Category: Food and Nutrition, Health Funding Amount: $750,000 |
| Single Source for continuation of the Human Pancreas Analysis Program for Type-2 Diabetes (HPAP-T2D) (U01 Clinical Trial Not Allowed) Apply for RFA DK 25 002 Funding Number: RFA DK 25 002 Agency: National Institutes of Health Category: Food and Nutrition, Health Funding Amount: $2,000,000 |
| Addressing the Impact of Syndemics on the Health of People with HIV and Diseases and Conditions within the Missions of NIDDK and NHLBI (R01 Clinical Trial Optional) Apply for RFA DK 25 001 Funding Number: RFA DK 25 001 Agency: National Institutes of Health Category: Food and Nutrition, Health Funding Amount: $500,000 |
| Cardiovascular Repository Type 1 Diabetes (CARE-T1D) Consortium (U01 Clinical Trial Not Allowed). Apply for RFA DK 23 021 Funding Number: RFA DK 23 021 Agency: National Institutes of Health Category: Food and Nutrition, Health Funding Amount: $600,000 |
| NIDDK Education Program Grants (R25 Clinical Trial Not Allowed) Apply for PAR 24 074 Funding Number: PAR 24 074 Agency: National Institutes of Health Category: Food and Nutrition, Health Funding Amount: $100,000 |
| NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Not Allowed) Apply for PAR 24 102 Funding Number: PAR 24 102 Agency: National Institutes of Health Category: Food and Nutrition, Health Funding Amount: Case Dependent |
| NIDDK High Risk Multi-Center Clinical Study Implementation Planning Cooperative Agreements (U34 Clinical Trial Optional) Apply for PAR 24 094 Funding Number: PAR 24 094 Agency: National Institutes of Health Category: Food and Nutrition, Health Funding Amount: $225,000 |
| NIDDK High Risk Multi-Center Clinical Study Cooperative Agreement (U01 Clinical Trial Required) Apply for PAR 24 103 Funding Number: PAR 24 103 Agency: National Institutes of Health Category: Food and Nutrition, Health Funding Amount: Case Dependent |
| Continuous Ketone Monitoring for the Safe Use of Sodium-glucose Cotransporter-2 Inhibitors in Type 1 Diabetes (R01 Clinical trial Required) Apply for RFA DK 23 011 Funding Number: RFA DK 23 011 Agency: National Institutes of Health Category: Food and Nutrition, Health Funding Amount: $500,000 |
| Impact of Comorbidities and Co-Infections on HIV Reservoirs (R01 Clinical Trial Not Allowed) Apply for RFA DK 25 013 Funding Number: RFA DK 25 013 Agency: National Institutes of Health Category: Food and Nutrition, Health Funding Amount: Case Dependent |
| Priority HIV/AIDS Research within the Mission of NIDDK (R01 Clinical Trial Optional) Apply for PAS 24 163 Funding Number: PAS 24 163 Agency: National Institutes of Health Category: Food and Nutrition, Health Funding Amount: Case Dependent |
| Elucidating Mechanisms Associated with HIV Related Co-Morbidities in Populations Experiencing Health Disparities (R01 - Clinical Trials Not Allowed) Apply for RFA MD 24 005 Funding Number: RFA MD 24 005 Agency: National Institutes of Health Category: Food and Nutrition, Health Funding Amount: $500,000 |
| Pilot Studies of Biological, Behavioral and Social Mechanisms Contributing to HIV Pathogenesis Within the Mission of NIDDK (R21 Clinical Trial Not Allowed) Apply for PAR 24 162 Funding Number: PAR 24 162 Agency: National Institutes of Health Category: Food and Nutrition, Health Funding Amount: Case Dependent |
| Diabetes Research Centers (P30 Clinical Trial Optional) Apply for RFA DK 25 008 Funding Number: RFA DK 25 008 Agency: National Institutes of Health Category: Food and Nutrition, Health Funding Amount: Case Dependent |
| Discovery of Early Type 1 Diabetes Disease Processes in the Human Pancreas [HIRN Consortium on Beta Cell Death and Survival (CBDS)] (U01 Clinical Trial Not Allowed) Apply for RFA DK 23 007 Funding Number: RFA DK 23 007 Agency: National Institutes of Health Category: Food and Nutrition, Health Funding Amount: $550,000 |
| Adaptation of Diabetes Control Technologies for Older Adults with T1D (R01 Clinical Trial Optional) Apply for RFA DK 24 002 Funding Number: RFA DK 24 002 Agency: National Institutes of Health Category: Food and Nutrition, Health Funding Amount: $500,000 |
| Kidney Technology Development Research Education Program (R25 - Independent Clinical Trial Not Allowed) Apply for RFA DK 25 009 Funding Number: RFA DK 25 009 Agency: National Institutes of Health Category: Food and Nutrition, Health Funding Amount: $130,000 |
| Cystic Fibrosis Research and Translation Centers (P30 Clinical Trial Optional) Apply for RFA DK 25 010 Funding Number: RFA DK 25 010 Agency: National Institutes of Health Category: Food and Nutrition, Health Funding Amount: $750,000 |
| Coordinating Center for Type 1 Diabetes TrialNet (U01 Clinical Trial Required) Apply for RFA DK 25 004 Funding Number: RFA DK 25 004 Agency: National Institutes of Health Category: Food and Nutrition, Health Funding Amount: Case Dependent |
| Type 1 Diabetes TrialNet Clinical Network Hub (U01 Clinical Trial Not Allowed) Apply for RFA DK 25 005 Funding Number: RFA DK 25 005 Agency: National Institutes of Health Category: Food and Nutrition, Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA DK 23 004", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.